0.4623
price up icon7.51%   0.0323
after-market 시간 외 거래: .49 0.0277 +5.99%
loading
전일 마감가:
$0.43
열려 있는:
$0.43
하루 거래량:
566.25K
Relative Volume:
0.22
시가총액:
$19.24M
수익:
-
순이익/손실:
$-74.56M
주가수익비율:
-0.2524
EPS:
-1.8316
순현금흐름:
$-60.27M
1주 성능:
+10.07%
1개월 성능:
+50.83%
6개월 성능:
-48.29%
1년 성능:
-65.50%
1일 변동 폭
Value
$0.4201
$0.485
1주일 범위
Value
$0.4003
$0.495
52주 변동 폭
Value
$0.2201
$1.54

Rallybio Corp Stock (RLYB) Company Profile

Name
명칭
Rallybio Corp
Name
전화
203- 859-3820
Name
주소
234 CHURCH STREET, NEW HAVEN
Name
직원
24
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
RLYB's Discussions on Twitter

RLYB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RLYB
Rallybio Corp
0.4623 17.48M 0 -74.56M -60.27M -1.8316
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Rallybio Corp Stock (RLYB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-09 다운그레이드 H.C. Wainwright Buy → Neutral
2024-05-15 다운그레이드 JP Morgan Overweight → Neutral
2024-02-07 다운그레이드 Jefferies Buy → Hold
2023-04-17 개시 H.C. Wainwright Buy
2023-04-10 개시 Wedbush Outperform
2022-12-09 개시 JP Morgan Overweight
2022-02-22 개시 JMP Securities Mkt Outperform
2021-08-23 개시 Cowen Outperform
2021-08-23 개시 Evercore ISI Outperform
2021-08-23 개시 Jefferies Buy
모두보기

Rallybio Corp 주식(RLYB)의 최신 뉴스

pulisher
03:19 AM

Rallybio Corporation Stock Analysis and ForecastExceptional trading performance - Autocar Professional

03:19 AM
pulisher
12:19 PM

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - Yahoo Finance

12:19 PM
pulisher
Jul 20, 2025

What drives Rallybio Corporation stock priceUnmatched market gains - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 19, 2025

What analysts say about Rallybio Corporation stockConsistently exceptional gains - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Is Rallybio Corporation a good long term investmentTremendous gains - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

10 Best Small Cap AI Stocks to Buy According to Analysts - Insider Monkey

Jul 18, 2025
pulisher
Jul 17, 2025

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN

Jul 17, 2025
pulisher
Jul 16, 2025

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Rallybio Corporation stock price move sharplyFree Best Performing Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Rallybio Corporation stock attracts strong analyst attentionFree Join Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Rallybio Corporation stock performs during market volatilityCarefully Curated High Return Stocks - Newser

Jul 15, 2025
pulisher
Jul 13, 2025

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - MSN

Jul 13, 2025
pulisher
Jul 11, 2025

Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN

Jul 11, 2025
pulisher
Jul 10, 2025

We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st

Jul 10, 2025
pulisher
Jul 09, 2025

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey

Jul 09, 2025
pulisher
Jul 09, 2025

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance

Jul 09, 2025
pulisher
Jul 09, 2025

Rallybio sells REV102 programme to Recursion for up to $25m - Pharmaceutical Business review -

Jul 09, 2025
pulisher
Jul 09, 2025

Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Rallybio sells HPP treatment program to Recursion for up to $25 million By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Rallybio sells HPP treatment program to Recursion for up to $25 million - Investing.com Nigeria

Jul 08, 2025
pulisher
Jul 08, 2025

Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize

Jul 08, 2025
pulisher
Jul 08, 2025

Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio - Investing.com India

Jul 08, 2025
pulisher
Jul 08, 2025

Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize

Jul 08, 2025
pulisher
Jul 08, 2025

Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - citybiz

Jul 08, 2025
pulisher
Jul 08, 2025

RallyBio - Hartford Business Journal

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio sells interest in drug program in deal worth up to $25M - Hartford Business Journal

Jul 08, 2025
pulisher
Jul 08, 2025

Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio shifts gears, cashing out of Recursion pact to extend runway - Fierce Biotech

Jul 08, 2025
pulisher
Jul 08, 2025

Recursion Pharmaceuticals Acquires Full Interest in Joint Hypophosphatasia Candidate From Rallybio - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ) - Seeking Alpha

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio sells interest in REV102 program to Recursion Pharmaceuticals - grafa.com

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio Sells REV102 Program to Recursion Pharmaceuticals - TipRanks

Jul 08, 2025
pulisher
Jul 07, 2025

ImmunoPrecise Strengthens Board with 30-Year Biotech Veteran Jon Lieber from Rallybio - Stock Titan

Jul 07, 2025
pulisher
Jun 27, 2025

Rallybio Finalizes Employment Agreement with CMO - TipRanks

Jun 27, 2025
pulisher
Jun 26, 2025

Rallybio’s FNAIT Study: A Closer Look at HPA-1a Alloimmunization - TipRanks

Jun 26, 2025
pulisher
Jun 26, 2025

Rallybio’s Phase 2 Study on RLYB212: A Potential Game-Changer for Pregnant Women at Risk - TipRanks

Jun 26, 2025
pulisher
Jun 13, 2025

Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study - TradingView

Jun 13, 2025

Rallybio Corp (RLYB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):